[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-glucose\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-glucose":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,54,88,117,140,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":4},"100645319","diabetes-insulin-gut-enteric-supplementation-trial-100645319",false,"NCT07682077","Diabetes, Insulin, Gut, Enteric Supplementation Trial","Effects of a Kefir Intervention in Pregnancy on Glucose, Insulin, Gestational Diabetes Mellitus, and the Gut Microbiome and Metabolites: A Randomized Controlled Trial","DIGEST","Inclusion Criteria:\n\n* Pregnant individual with a singleton pregnancy\n* 19 years and older of age\n* Gestational age 14,3 weeks or less at enrolment\n* Able and willing to attend four in-person study visits at the PEADS Laboratory: baseline, 18-20 weeks' gestation, 26-28 weeks' gestation, and 1 month postpartum\n* Willing and able to comply with study group assignment, including daily consumption of 250 mL of kefir if assigned to the intervention group\n* Willing to avoid kefir consumption until completion of the 26-28-week study visit if assigned to the control group\n* Willing to provide required biological and clinical samples, including stool samples and glucose\u002Finsulin data, according to the study protocol\n* No probiotic, prebiotic, synbiotic, or antibiotic use during the first trimester or at enrollment\n* Not currently consuming probiotic, prebiotic, synbiotic, or antiobiotic supplements\n* Willing to avoid probiotic, prebiotic, and synbiotic supplements until completion of the 26-28-week study visit.\n* Does not engage in regular moderate-to-vigorous physical activity\n* No recent or active infectious illness or significant gastrointestinal symptoms, including diarrhea or constipation in the first trimester of pregnancy.\n* No history of bariatric surgery\n* Able to communicate in English or French\n* Currently living in Fredericton, New Brunswick, and not planning to relocate before the 1-month postpartum visit\n\nExclusion Criteria:\n\n* Pre-existing metabolic disease affecting glucose regulation, including type 1 diabetes or type 2 diabetes\n* Current use or first trimester use of medications known to alter glucose metabolism, such as metformin or semaglutide\n* Gastrointestinal or inflammatory disease, including Crohn's disease, ulcerative colitis, celiac disease, or diagnosed irritable bowel syndrome\n* Allergy, intolerance, or other contraindication to dairy or components of kefir",true,"FEMALE","19 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Pregnancy is a critical window for metabolic health, and early changes in blood sugar regulation can increase the risk of gestational diabetes mellitus (GDM), which affects both maternal and infant health. At the same time, the maternal gut microbiome changes throughout pregnancy and may play a role in glucose metabolism and insulin resistance. Kefir, a fermented milk drink containing beneficial bacteria and yeasts, may be a simple dietary strategy to support metabolic health during pregnancy, but its role in preventing GDM has not been well studied.\n\nThis study will test whether drinking kefir daily from mid-pregnancy until routine GDM screening can improve glucose and insulin regulation, reduce the incidence of GDM, and modulate the maternal gut microbiome and metabolites, among other outcomes.\n\nPregnant individuals will be randomly assigned to either a kefir group or a control group receiving usual prenatal care. Researchers will collect blood glucose and insulin measures, dietary information, stool samples, and body composition data across pregnancy and postpartum to evaluate metabolic and microbiome-related changes.\n\nAs one of the first studies to examine kefir as an early pregnancy intervention for GDM prevention, this study will help clarify whether a practical, food-based approach can improve maternal metabolic health. The findings may support future nutrition strategies aimed at reducing GDM risk and improving pregnancy outcomes.",[28,29,30,31,32],"Gestational Diabetes Mellitus (GDM)","Blood Glucose","Insulin Resistance, Diabetes","Gut Microbiome","Gut Metabolites",[34,35,36,37,38,39,40,41],"Gestational diabetes mellitus","Pregnancy","Probiotics","Kefir","Gut microbiome","Gut metabolites","Glucose","Insulin","NOT_YET_RECRUITING","2026-06-30",{"date":45,"type":46},"2026-07-02","ACTUAL",{"date":48,"type":22},"2026-06-01",{"date":50,"type":22},"2029-06-01",{"name":52,"class":53},"University of New Brunswick","OTHER",{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":17,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100636963","slowly-digestible-carbohydrates-for-glp-1-secretion-100636963","NCT07572513","Slowly Digestible Carbohydrates for GLP-1 Secretion","Inclusion Criteria:\n\n1. Healthy population\n2. BMI between 18.5 and 24.9 kg\u002Fm2\n3. Adults 18 - 45 years old\n4. Men or women\n5. Able to read\u002Fspeak English\n6. Fasting blood glucose levels ≤100 mg\u002FdL\n7. HbA1c ≤ 5.7%\n\nExclusion Criteria:\n\n1. Participants with 18 \\> Years of Age \\> 45 will be excluded.\n2. Subjects with 18.5 kg\u002Fm² \\> BMI \\> 24.9 kg\u002Fm² will be excluded.\n3. Diabetic individuals will be excluded.\n4. Individuals with history of gastrointestinal disease will be excluded from the study.\n5. Pregnant or nursing women will also be excluded.\n6. Individuals taking GLP-1 medications, or on weight-loss diets or restrictive eating patterns.\n7. Individuals suffering from dairy or gluten intolerance or allergies will be excluded.","ALL","18 Years","45 Years",{"count":64,"type":22},19,[25],"The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss.\n\nResearchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 60, 120, 180 minutes and after a second meal.\n\nThere will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will:\n\n* Consume a randomized test beverage (SDC or maltodextrin)\n* Receive a blood draw at 7 timepoints over 3 hrs\n* Take a satiety questionnaire 5 times over 3 hrs\n* Consume a standardized lunch 3 hrs after the test beverage consumption",[29,68,69,70,71],"GLP-1","Satiety","Second Meal Intake","Healthy Participant Study",[68,73,74,75,69,76,77,29],"Slowly-Digestible Starch","Ileal-Digesting Starch","Dietary Starch","Starch","raw corn starch","RECRUITING","2026-05-01",{"date":81,"type":46},"2026-05-07",{"date":79,"type":22},{"date":84,"type":22},"2026-11-25",{"name":86,"class":53},"Purdue University",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":17,"sex":60,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":87},"100596286","a-clinical-trial-to-investigate-the-efficacy-of-bragg-apple-cider-vinegar-on-blood-glucose-control-in-a-healthy-adult-population-100596286","NCT07043478","A Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population","A Randomized, Single-blind, Controlled, Cross-over Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population","Inclusion Criteria:\n\nMales and females 20 - 50 years of age, inclusive 2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\nOr,\n\nIndividuals of child-bearing potential must have a negative screening urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n\n* Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n* Double-barrier method\n* Intrauterine devices\n* Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n* Vasectomy of partner at least 6 months prior to screening\n* Abstinence and agrees to use contraception if planning on becoming sexually active during the study 3. Subjects with elevated fasting glucose \\> 5.6 mmol\u002FL (\\> 100 mg\u002FdL) and \\\u003C 7.0 mmol\u002FL (\\\u003C 126 mg\u002FdL) and\u002For elevated HbA1c (6.0-6.4%) and two or more of the other following markers associated with metabolic syndrome at screening:\n\n  1. Abdominal obesity: waist circumference \\> 102 cm (40 inches) in men and \\> 88 cm (35 inches) in women\n  2. Hypertension: systolic blood pressure \\> 130 mmHg or diastolic blood pressure \\> 85 mmHg\n  3. Elevated TG: \\> 150 mg\u002FdL (1.7 mmol\u002FL)\n  4. Low HDL-C: \\\u003C 40 mg\u002FdL (1.03 mmol\u002FL) in men and \\\u003C 50 mg\u002FdL (1.29 mmol\u002FL) in women 4. Stable body weight defined as a \\\u003C5% change in body weight in the three months prior to baseline, as assessed by the Qualified Investigator (QI) 5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study 6. Agrees to comply with dietary guidelines and study requirements prior to in-clinic visits (see Section 9.1) 7. Provided voluntary, written, informed consent to participate in the study 8. Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI)\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity or intolerance, preventing consumption of investigational product, placebo, or standardized meal\n3. Poor venous access as assessed by the QI\n4. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the glucose metabolism or efficacy of the investigational product (Sections 7.3.1 and 7.3.2)\n5. Unstable metabolic disease or chronic diseases as assessed by the QI\n6. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n7. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n8. Type I or Type II diabetes\n9. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n10. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n11. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n12. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n13. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n14. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n15. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n16. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by the QI\n17. Chronic inhalation or edible use of cannabinoid products (\\>1 time\u002Fmonth). Occasional users must agree to abstain from use while participating in the study\n18. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n19. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n20. Alcohol or drug abuse within the last 12 months\n21. Clinically significant abnormal laboratory results at screening as assessed by the QI\n22. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n23. Participation in other clinical research studies 30 days prior to baseline as assessed by the QI\n24. Individuals who are unable to give informed consent\n25. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","20 Years","50 Years",{"count":98,"type":22},24,[25],"The goal of this clinical study is to investigate the efficacy of a Bragg Apple Cider Vinegar (ACV) liquid on postprandial glucose (PPG) excursion compared to a placebo following a standardized acute carbohydrate load. The main question it aims to answer is:\n\nIs there a difference in the incremental area under the curve (iAUC) (from 0 - 120 mins following administration) for venous blood glucose between Bragg ACV liquid and placebo following an acute carbohydrate load.\n\nParticipants will \\[describe the main tasks participants will be asked to consume 750 mg of Bragg Apple Cider Vinegar (ACV) liquid or water and undergo a blood draw to measure glucose, insulin, and future analysis markers.",[102,29],"Healthy",[104,105,106],"Blood glucose control","Bragg Apple Cider Vinegar","Apple Cider Vinegar","2026-03-05",{"date":109,"type":46},"2026-03-06",{"date":111,"type":46},"2025-08-05",{"date":113,"type":22},"2026-03",{"name":115,"class":116},"Bragg Live Food Products","INDUSTRY",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":17,"sex":60,"minAge":19,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":87},"100559773","dairy-and-vegan-cheese-effect-on-satiety-and-blood-glucose-100559773","NCT06568497","Dairy and Vegan Cheese: Effect on Satiety and Blood Glucose","Sensory, Satiating and Glycaemic Characteristics of Cheese and Non-dairy Alternative Products to Cheese","Inclusion Criteria:\n\n* Young healthy adults\n\nExclusion Criteria:\n\n* Breakfast skipper\n* Smoker (including e-cigarettes) \u002F cannabis consumer\n* Be underweight, overweight or obese\n* Have chronic diseases, including diabetes\n* Taking certain medication\n* Have lactose intolerance, food allergies or gastrointestinal disorders (e.g., irritable bowel syndrome, or others).","35 Years",{"count":126,"type":22},52,[25],"The project will consist of two studies. One study will explore the satiating properties of dairy cheese and its dairy-free substitute when consumed ad libidum, and another study will investigate their effects on postprandial glycemia. Both studies will involve healthy young adults. The secondary outcomes of these studies will be food sensory characteristics, diet-induced thermogenesis, subjective feeling of fatigue and energy, gastrointestinal comfort level, and food intake. The proposed project results will help to better understand the health properties of the cheese and its dairy-free substitute.",[29,130],"Satiety Response","2025-08-22",{"date":133,"type":46},"2025-08-29",{"date":135,"type":46},"2024-08-04",{"date":137,"type":22},"2025-12-31",{"name":139,"class":53},"Mount Saint Vincent University",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":17,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":87},"100600868","postprandial-response-to-fruit-juice-100600868","NCT07103083","Postprandial Response to Fruit Juice","A Randomized, Crossover, Controlled Trial Investigating the Effects of Different Cranberry-Based Beverages on Postprandial Glucose, Insulin, and GLP-1","Inclusion Criteria:\n\n1. ≥18 to ≤45 years of age at Visit 1.\n2. BMI ≥18.5 and \\\u003C30.0 kg\u002Fm2 at Visit 1.\n3. Fasting capillary glucose ≤110 mg\u002FdL at Visit 1.\n4. Willing to avoid consuming high-polyphenol containing foods for 48 hours prior to each test visit.\n5. Willing to abstain from alcohol consumption for 24 hours prior to each study visit.\n6. Non-user of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of Visit 1, with no plans to begin use during the study period.\n7. Non-habitual users (i.e., daily or almost daily) of marijuana or hemp products, including Cannabidiol (CBD)\u002FTetrahydrocannabinol (THC) products, and willing to abstain from use throughout the study period (topical creams\u002Flotions are allowed).\n8. Willing to maintain habitual physical activity level throughout the duration of the study.\n9. Willing to maintain habitual dietary pattern throughout the duration of the study, including stable intake of current vitamins, minerals, supplements and medications not interfering with study outcomes.\n10. Score of 7 to 10 on the Vein Access Scale at Visit 1.\n11. No health conditions that would prevent him\u002Fher from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history.\n12. Understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Clinical Investigator.\n\nExclusion Criteria:\n\n1. History or presence of clinically important cardiac, renal, hepatic, endocrine, pulmonary, biliary, pancreatic, gastrointestinal, or neurological disorders that may affect the participant's ability to adhere to the study protocol and\u002For affect study outcomes, in the judgment of the Clinical Investigator.\n2. Uncontrolled hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) as defined by the blood pressure measured at Visit 1 (Section 9.1.1).\n3. Unstable use (initiation or change in dose) within 30 days of Visit 1 of antihypertensive medications.\n4. Unstable use (initiation or change in dose) within 30 days of Visit 1 of thyroid hormone replacement medications.\n5. Use of medications or supplements that may influence carbohydrate metabolism within 30 days of Visit 1.\n6. Extreme dietary habits (e.g., ketogenic, very high protein, very high fiber, vegan, vegetarian) at the discretion of the Clinical Investigator.\n7. Weight loss or gain \\>4.5 kg in the 60 days prior to Visit 1.\n8. Currently, or planning to be, on a weight loss regimen during the study.\n9. Use of weight loss medication within 90 days of Visit 1.\n10. History of gastrointestinal surgery for weight reducing purposes.\n11. History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.\n12. Known allergy or sensitivity to any ingredients or potential allergens contained in the study beverages.\n13. History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.\n14. History of any major trauma or major surgical event within 60 days of Visit 1.\n15. Blood donation \\>450 mL within 60 days of Visit 2 or plans to donate blood or plasma during the study period.\n16. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential with unstable use (initiation or change in dose) within 30 days of Visit 1) of sex hormones for contraception.\n17. Recent history of (within 12 months of screening; Visit 1) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as \\>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).\n18. Exposed to any non-registered drug product within 30 days prior to Visit 1.\n19. Any condition the Clinical Investigator believes would interfere with the participant's ability to provide informed consent or comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.",{"count":148,"type":22},18,[25],"The goal of this clinical trial is to determine postprandial responses to fruit juices.",[29,152],"Blood Insulin",[154,155,156],"fruit juice","blood glucose","metabolic health","2025-07-28",{"date":111,"type":46},{"date":160,"type":46},"2025-07-21",{"date":162,"type":22},"2025-10-29",{"name":164,"class":116},"Ocean Spray Cranberries, Inc.",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":17,"sex":60,"minAge":61,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":185,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":87},"100546699","identifying-wearable-biomarkers-to-monitor-dietary-intake-100546699","NCT06398340","Identifying Wearable Biomarkers to Monitor Dietary Intake","Identifying Physiological Biomarkers for Monitoring Dietary Behaviours","FoodSense","Inclusion Criteria:\n\n* Male or female\n* Age between 18-65 years (inclusive)\n* Body mass index (BMI) of 18-30 kg\u002Fm2\n* Willingness and ability to give written informed consent.\n* Willingness and ability to understand, to participate and to comply with the study requirements\n\nExclusion Criteria:\n\n* Outside of specified age and BMI range\n* Chronic medical conditions including for eating disorders, diabetes, obesity, hypertension, cancer, acute infectious disease, renal disease, cardiovascular disease, and chronic gastrointestinal condition.\n* Taking part in another research study or donating any blood in the last 3 months","65 Years",{"count":175,"type":22},10,[25],"Background: Measuring what people eat is a challenge in nutrition research. Traditional methods, like food diaries, rely on self-reporting of individuals, and suffer from poor accuracy and recall bias.\n\nAims: This project aims to identify physiological biomarkers related to food and energy intake, which may be used to develop an objective tool to estimate individuals' food intake in future. Eating behaviours are accompanied by significant physiological changes such as skin temperature, blood oxygen saturation, pulse rate etc. The investigators intend to investigate whether monitoring these physiological changes can help us estimate eating behaviour, such as meal size, eating speed, and duration of meals.\n\nStudy design: Ten healthy adults will be invited for two study visits at NIHR Imperial Clinical Research Facility. Each visit will last for approximately 2 hr. They will consume a high- and low-calorie meal designed by nutritional researchers in a randomised order. During eating events, the investigators will track their physiological changes via a bedside monitor and wearable sensors. Blood samples will be taken from participants to measure their glycaemic response. Associations between energy load, glycaemic response, and physiological changes will be investigated. Our findings may promote an accelerated development of a wearable tool for dietary assessment in future.",[179,180,181,182,183,184,29],"Energy Intake","Metabolism","Digestion","Wearables","Dietary Intake Assessment","Healthy Volunteers",[186,187,188,155],"Dietary intake monitoring","wearable sensors","digital health","2025-02-17",{"date":191,"type":46},"2025-02-18",{"date":193,"type":46},"2024-08-19",{"date":195,"type":22},"2025-07-31",{"name":197,"class":53},"Imperial College London"]